The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp465
PANEL DISCUSSION
Date
May 7, 2023
Explore related products in the following collection:
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
BACKGROUND: The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST) pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes following in-utero exposure require elucidation…